PRLD Prelude Therapeutics Inc

Nasdaq preludetx.com


$ 1.34 $ 0.03 (2.29 %)    

Wednesday, 15-Oct-2025 12:40:07 EDT
QQQ $ 602.49 $ -1.31 (-0.22 %)
DIA $ 463.47 $ -1.21 (-0.26 %)
SPY $ 664.93 $ -1.85 (-0.28 %)
TLT $ 90.68 $ -0.27 (-0.3 %)
GLD $ 385.79 $ -0.17 (-0.04 %)
$ 1.3
$ 1.34
$ 1.34 x 16
$ 1.36 x 2,000
$ 1.30 - $ 1.34
$ 0.61 - $ 2.01
76,337
na
73.58M
$ 1.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-10-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-15-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-15-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-16-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

 jmp-securities-maintains-market-outperform-on-prelude-therapeutics-lowers-price-target-to-3

JMP Securities analyst Reni J. Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and lowers the...

 prelude-therapeutics-q1-eps-042-beats-047-estimate

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

 jmp-securities-reiterates-market-outperform-on-prelude-therapeutics-maintains-4-price-target

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and maintains $4...

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

 citizens-capital-markets-reiterates-market-outperform-on-prelude-therapeutics-maintains-4-price-target

Citizens Capital Markets analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and ma...

 prelude-therapeutics-fy-sales-7000m-beat-2000m-estimate

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly sales of $7.000 million which beat the analyst consensus estimate of $2.0...

 jmp-securities-reiterates-market-outperform-on-prelude-therapeutics-lowers-price-target-to-4

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and lowers the p...

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION